<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002448</url>
  </required_header>
  <id_info>
    <org_study_id>229S</org_study_id>
    <secondary_id>M61028</secondary_id>
    <nct_id>NCT00002448</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients</brief_title>
  <official_title>Evaluation of Immune Reconstitution in HIV Infected Patients Treated With Fortovase (Saquinavir) SGC QD Plus Ritonavir QD Plus 2 NRTIs Vs Efavirenz QD Plus 2 NRTIs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine how the immune systems of HIV-infected patients react
      to 2 anti-HIV drug combinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to two study arms for at least 48 weeks of treatment. Arm A receives
      SQV SGC plus RTV plus two NRTIs of choice. Arm B receives EFV plus two NRTIs of choice. NRTIs
      approved for study use are stavudine (d4T), didanosine (ddI), zidovudine (AZT), lamivudine
      (3TC), Combivir, and zalcitabine (ddC). Abacavir is excluded. The following immunology
      variables and HIV-1 viral characteristics will be evaluated during study visits: CD4 and CD8
      cell counts; naive and memory T-cells; T-cell activation markers (HLA-DR and CD38); T-cells
      expressing T helper 1- (TH1-) and T helper 2- (TH2-) associated intracytoplasmic cytokines;
      anti-CD3 T-cell activation responses; T-cell receptor V Beta repertoire; cytotoxic
      T-lymphocyte (CTL) activity levels; lymph node histology (optional); HIV-1 qualitative
      microcultures and viral phenotyping for non-syncytium-inducing (NSI) and syncytium-inducing
      (SI) viral isolates. Laboratory determinations, adverse effects, neurological exams
      (including mental status evaluations), and lipodystrophy parameters (including fasting lipid
      profile and physical parameters) also are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients may be eligible for this study if they:

          -  Are HIV-positive.

          -  Have a viral load of at least 5,000 copies/ml and a CD4 cell count greater than 75
             cells/mm3.

          -  Are at least 16 (need consent of parent or guardian if under 18).

          -  Are able to complete the study.

        Exclusion Criteria

        Patients will not be eligible for this study if they:

          -  Have ever taken anti-HIV medications.

          -  Are pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Holodniy</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Joseph John</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Ronald Mitsuyasu</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Care Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900951793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Alto Veterans Affairs Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Med School/UMDNJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>089030019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Dosage Forms</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>efavirenz</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

